Dulaglutide vs 5-Amino-1MQ
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Trulicity
Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. It is FDA-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. The once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents.
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
First, a correction worth making loudly: 5-amino-1MQ is not a peptide. It is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. It blocks an enzyme called NNMT, and in obese mice it produced weight and fat loss without the animals eating less. No human trials have been published.
Key Comparison Insights
- Dulaglutide is FDA approved, while 5-Amino-1MQ remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | Dulaglutide | 5-Amino-1MQ |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dulaglutide activates the GLP-1 receptor, mimicking the natural incretin hormone your gut releases after eating. It prompts glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying, so blood sugar drops after meals without driving dangerous lows. The antibody (Fc) portion bolted onto the peptide makes the molecule too large for the kidneys to quickly clear and shields it from the DPP-4 enzyme that destroys natural GLP-1 within minutes. That engineering is the entire reason a once-weekly schedule works. The appetite and modest weight effects come from the same GLP-1 signaling in brain regions that regulate hunger. | NNMT (nicotinamide N-methyltransferase) takes nicotinamide and tags it with a methyl group borrowed from SAM, the cell's main methyl donor, producing 1-methylnicotinamide. In fat tissue, high NNMT activity is thought to drain both NAD+ precursors and SAM, nudging cells toward storing fat. The hypothesis behind 5-amino-1MQ is straightforward: inhibit NNMT, and you preserve NAD+ and SAM inside adipocytes, which shifts them away from fat storage and toward burning energy. The published mouse work showed NNMT inhibition raising intracellular NAD+ and SAM, consistent with that idea. It is a plausible, well-reasoned mechanism, but in humans it remains a hypothesis, not a demonstrated effect. |
| Common Dosing | 1.5-4.5 mg weekly Once weekly | 50-75 mg daily Once daily, morning |
| Administration | Subcutaneous injection weekly | Subcutaneous injection or oral |
| Typical Duration | Long-term / chronic use | 4-6 weeks (cycling recommended) |
| Best Time to Take | Before bed or morning (fasted) | Morning, fasted |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Dulaglutide is backed by extensive human trials, not animal models. The AWARD program established its glucose-lowering efficacy across many type 2 diabetes settings. The landmark REWIND trial, published in The Lancet in 2019, followed over 9,900 patients for a median of more than five years and was unusual because most participants (about 69%) had no prior cardiovascular disease. It found dulaglutide reduced major cardiovascular events (cardiovascular death, heart attack, or stroke) versus placebo, 12.0% vs 13.4%, a hazard ratio of 0.88. That made it one of the first GLP-1 agents with evidence supporting both primary and secondary cardiovascular prevention. The typical downsides are gastrointestinal (nausea, diarrhea), and like others in the class it carries a boxed warning about thyroid C-cell tumors based on rodent data. | The headline study (Neelakantan et al.) tested small-molecule NNMT inhibitors in diet-induced obese mice. Treated animals lost weight (roughly 5% from baseline over about 11 days in that work) and shed white adipose mass, with reduced circulating cholesterol and no change in food intake, which points to a metabolic effect rather than appetite suppression. That is genuinely interesting preclinical data. But here is the honest part: the entire evidence base is animal and cell studies. There are no published human clinical trials demonstrating that 5-amino-1MQ causes fat loss, raises energy expenditure, or is safe over time in people. Claims of specific human fat-loss percentages from vendors are not backed by trial data. Treat it as an early-stage research compound, not a proven product. |
Frequently Asked Questions: Dulaglutide vs 5-Amino-1MQ
What is the difference between Dulaglutide and 5-Amino-1MQ?
Dulaglutide is a weight loss peptide that dulaglutide (brand name trulicity) is a once-weekly injectable glp-1 receptor agonist made by fusing a modified glp-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. it is fda-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. the once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents. 5-Amino-1MQ is a weight loss peptide that first, a correction worth making loudly: 5-amino-1mq is not a peptide. it is a small molecule (5-amino-1-methylquinolinium), and it gets lumped in with research peptides mostly because of the crowd that sells it. it blocks an enzyme called nnmt, and in obese mice it produced weight and fat loss without the animals eating less. no human trials have been published. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dulaglutide or 5-Amino-1MQ?
Neither is universally "better" - the choice depends on your specific goals. Dulaglutide is typically used for weight loss purposes, while 5-Amino-1MQ is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dulaglutide and 5-Amino-1MQ be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dulaglutide and 5-Amino-1MQ together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.